XT
STRO icon

XTX Topco’s Sutro Biopharma STRO Stock Holding History

XTX Topco’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73M Buy
52,169
+43,966
+536% +$1.37M 0.02% 1257
2026
Q1 		$204K Buy
+8,203
New +$148K ﹤0.01% 2832
2025
Q4 		– Sell
-1,913
Closed -$16.6K – 3778
2025
Q3 		$16.6K Buy
+1,913
New +$16.3K ﹤0.01% 2362
2025
Q2 		– Sell
-2,517
Closed -$16.4K – 3133
2025
Q1 		$16.4K Buy
2,517
+336
+15% +$5.29K ﹤0.01% 2182
2024
Q4 		$40.1K Sell
2,181
-8,239
-79% -$252K ﹤0.01% 1934
2024
Q3 		$361K Buy
10,420
+7,184
+222% +$282K 0.03% 1070
2024
Q2 		$94.8K Sell
3,236
-5,654
-64% -$224K 0.01% 1428
2024
Q1 		$502K Buy
8,890
+591
+7% +$26.1K 0.07% 486
2023
Q4 		$356K Buy
8,299
+6,254
+306% +$198K 0.08% 491
2023
Q3 		$70.9K Buy
+2,045
New +$89.1K 0.01% 1229
2023
Q2 		– Sell
-10,078
Closed -$466K – 1819
2023
Q1 		$466K Sell
10,078
-59
-0.6% -$3.74K 0.1% 336
2022
Q4 		$819K Buy
10,137
+4,375
+76% +$304K 0.17% 131
2022
Q3 		$320K Buy
5,762
+2,244
+64% +$133K 0.08% 463
2022
Q2 		$183K Buy
+3,518
New +$197K 0.07% 488

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

XTX Topco's STRO Position: Q2 2026 in Review

XTX Topco increased its Sutro Biopharma (STRO) stake by 536% in Q2 2026, buying an estimated $1.37M and bringing the position to 52,169 shares worth $1.73M. The position accounts for 0.02% of the portfolio, ranked #1257.

XTX Topco first reported a position in STRO in Q2 2022 and has held it in 14 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • XTX Topco held 52,169 shares of Sutro Biopharma worth $1.73M as of Q2 2026.
  • XTX Topco bought 43,966 Sutro Biopharma shares in Q2 2026, an estimated $1.37M.
  • Sutro Biopharma made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1257 holding.
  • XTX Topco first reported a position in Sutro Biopharma in Q2 2022 and has held it in 14 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.